Tango Therapeutics, Inc.
TNGX
Clasificación en acciones
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Precio por acción
$27.18
Última sincronización: 2026-07-31
Capitalización bursátil
$3.38B
Cambio (1 día)
-1.41%
Cambio (1 año)
202.34%
País
US
Comercio Tango Therapeutics, Inc. (TNGX)
Categoría
Healthcare
Ganancias de Tango Therapeutics, Inc. (TNGX)
Ganancias en Jun 2026 TTM: $-123.78M
Secondo gli ultimi rapporti finanziari di Tango Therapeutics, Inc., gli utili attuali della società sono $-123.78M. Nel 2023, la società ha registrato un utile di $-101.61M, un aumento con respecto a agli utili del 2022, che erano di $-108.12M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Tango Therapeutics, Inc. desde 2019 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
